Note 14  Segment Information  Abbotts principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbotts products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians offices and government agencies throughout the world.  Abbotts reportable segments are as follows:  Established Pharmaceutical Products  International sales of a broad line of branded generic pharmaceutical products.  Nutritional Products  Worldwide sales of a broad line of adult and pediatric nutritional products.  Diagnostic Products  Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, physician offices and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.  Medical Devices  Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology and Heart Failure, Vascular, Neuromodulation, Structural Heart and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.  Abbotts underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segments assets.  The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.                             Net Sales to External Customers  Operating Earnings   Three Months  Nine Months  Three Months  Nine Months   Ended September 30  Ended September 30  Ended September 30  Ended September 30 (in millions) 2020 2019 2020 2019 2020 2019 2020 2019 Established Pharmaceutical Products  $ 1,099  $ 1,212  $ 3,156  $ 3,312  $ 201  $ 281  $ 588  $ 654 Nutritional Products  1,924  1,874  5,711  5,541  394  414  1,327  1,241 Diagnostic Products  2,640  1,909  6,460  5,655  875  456  1,802  1,356 Medical Devices  3,170  3,065  8,530  9,035  928  958  2,122  2,722 Total Reportable Segments  8,833  8,060  23,857  23,543  2,398  2,109  5,839   5,973 Other  20  16  50  47             Net sales  $ 8,853  $ 8,076  $ 23,907  $ 23,590             Corporate functions and benefit plan costs              (129)   (131)   (367)   (332) Net interest expense              (127)   (143)   (373)   (437) Share-based compensation (a)              (100)   (94)   (448)   (434) Amortization of intangible assets              (510)   (484)   (1,624)   (1,453) Other, net (b)              (111)   (154)   (447)   (480) Earnings from continuing operations before taxes              $ 1,421  $ 1,103  $ 2,580  $ 2,837 (a) Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. (b) Other, net for the three and nine months ended September 30, 2020 and 2019 includes integration costs associated with the acquisition of St. Jude Medical and Alere, and restructuring charges. Other, net for the three and nine months ended September 30, 2020 also includes costs related to asset impairments, partially offset by income from the settlement of litigation. Other, net for the nine months ended September 30, 2019 includes charges associated with R&amp;D assets acquired and immediately expensed.